ATIR101 is an immunotherapeutic delivered as an adjunctive therapy for patients receiving HSCT. It repletes a patient’s immune system following HSCT through a single dose donor lymphocyte infusion, which helps prevent infections and disease relapse until the patient’s own immune system function is restored. Prior to infusion, alloreactive T-cells from the donor lymphocyte infusion are removed via the activation of a photodynamic compound (TH9402) with the proprietary Theralux device, negating the risk of developing graft-versus-host disease.
LIST OF FIGURES
8 Figure 1: ATIR101 for acute myeloid leukemia – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of ATIR101 for acute myeloid leukemia
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of ATIR101 for acute myeloid leukemia
LIST OF TABLES
5 Table 1: ATIR101 drug profile
6 Table 2: ATIR101 late-phase trials in acute myeloid leukemia
8 Table 3: ATIR101 Phase II trial data in acute myeloid leukemia
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.